TransCode Therapeutics Starts Dosing for Experimental Cancer Treatment in Early Trial

Important legal information about the email you will be sending. By using this service, you agree to input your real email address and only send it to people you know. It is a violation of law in some jurisdictions to falsely identify yourself in an email. All information you provide will be used by Fidelity solely for the purpose of sending the email on your behalf. The subject line of the email you send will be "Fidelity.com: "

TransCode Therapeutics Starts Dosing for Experimental Cancer Treatment in Early Trial

, MT Newswires - 5:32 PM ET 3/27/2025 default

05:32 PM EDT, 03/27/2025 (MT Newswires) -- TransCode Therapeutics ( RNAZ ) started dosing the first patient in the fourth cohort of its phase 1 cancer treatment trial.

Two more patients in the cohort are set to receive the TTX-MC138 "to inhibit microRNA-10b, a microRNA critical to the emergence and progression of metastatic cancer," the company said Thursday in a statement.

"No significant safety or dose limiting toxicities have been reported," and additional patients are being evaluated for expanded enrollment, the company said.

Shares of the company rose 28% in after-hours trading.

Price: 0.6650, Change: +0.15, Percent Change: +27.88

MT Newswires does not provide investment advice. Unauthorized reproduction is strictly prohibited.